First-in-Human Use of ONWARD’s Implantable Neurostimulator

Please login or
register
10.05.2022
Onward ARC

ONWARD’s ARC implantable pulse generator (IPG) is designed to stimulate the spinal cord to restore movement and autonomic function for people with spinal cord injury and other conditions that affect mobility. This first implant is a major milestone in ONWARD’s development of implantable neurostimulation technology to help people with spinal cord injury.

The ONWARD ARC IPG was purpose-designed to deliver targeted electrical stimulation to the spinal cord in the precise areas responsible for triggering or controlling movement and autonomic functions that may be affected by a spinal cord injury or neurodegenerative disorder. It allows clinicians to apply biomimetic stimulation that can closely replicate normal spinal cord activity patterns during mobility or autonomic function.

The HemON Study (NCT05111093) aims to evaluate the safety and preliminary efficacy of ARC Therapy to improve blood pressure management and trunk control in people with spinal cord injury who suffer from orthostatic hypotension, which is characterized by debilitatingly low blood pressure that may occur when people sit upright, stand, or change body position. Orthostatic hypotension has been observed in approximately 75% of people with spinal cord injury. HemON will enroll up to 16 participants at CHUV in Lausanne, Switzerland.

“The first implant of our ARC IPG is a huge milestone for ONWARD and the SCI community,” said Dave Marver, CEO of ONWARD. “This important achievement validates our vision for a future in which clinicians will no longer need to struggle with modified pain stimulators to explore new treatments and instead will be able to use devices and therapies designed specifically to treat people with spinal cord injury and their unique needs.”

(Press release / SK)

0Comments

More news about

ONWARD Medical SA

Company profiles on startup.ch

ONWARD Medical SA

rss